Breaking boundaries: ReleGO™ & REVex™ Pushes the Boundaries of Native Skin Viability up to 20 days for Ex-Vivo Studies

ReleGO & REVex organ-on-a-chip technology

A revolutionary achievement

Preserving the vitality of native human skin explants has long been a challenge, limiting the potential for conducting in-depth, long-term studies. In traditional plasticware and static setups, the rapid deterioration of the viable epidermis and dermis restricts testing periods for cosmetic and dermatological products to just 7 days post-harvest. This constrains the insights that can be gained on the long-term effects of native skin explants.

By harnessing the innovative microfluidic capabilities of ReleGO™ and the REVex™ chip by REVIVO BioSystems , we have successfully expanded the “usable window” for native skin explants to an impressive 20 days. This groundbreaking accomplishment is crucial for gaining deeper insights into the long-term impacts of your ingredients and products, whether used in single or repeated doses.

Follow the timeline of the H&E sections below to see firsthand how, when culturing native human skin on our ReleGO™ & REVex™ platform, the viability and morphology of the epidermis are meticulously preserved and sustained for a remarkable 20-day period. This level of preservation and longevity is simply unattainable with a static culture approach.

Revex chip for skin viability

This groundbreaking demonstration marks a significant milestone, paving the way for innovative studies on formulations and ingredients, as well as advancements in transdermal and subdermal delivery research.

Follow us for the latest updates on how microfluidic technology can revolutionize the way you cultivate native human skin explants for long-term studies, propelling your research in cosmetics, dermatology, and transdermal applications to new heights.